

Daniel W Coyne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2292103/publications.pdf>

Version: 2024-02-01

65
papers

3,107
citations

257450

24
h-index

155660

55
g-index

68
all docs

68
docs citations

68
times ranked

2630
citing authors

#	ARTICLE	IF	CITATIONS
1	Proactive high-dose IV iron is preferred therapy in ESKD patients: PRO. <i>Kidney360</i> , 2022, 3, 10.34067/KID.0002442021.	2.1	0
2	Groundhog Day: research without old data and old references. <i>Psychological Medicine</i> , 2022, 52, 625-631.	4.5	3
3	Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. <i>Journal of Nephrology</i> , 2022, 35, 875-888.	2.0	5
4	Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort. <i>International Journal of Nephrology and Renovascular Disease</i> , 2022, Volume 15, 139-149.	1.8	0
5	Roxadustat for CKD-related Anemia in Non-dialysis Patients. <i>Kidney International Reports</i> , 2021, 6, 624-635.	0.8	65
6	Phosphate Balance and CKDâ€™Mineral Bone Disease. <i>Kidney International Reports</i> , 2021, 6, 2049-2058.	0.8	22
7	Will Targeting Interleukin-6 in the Anemia of CKD Change Our Treatment Paradigm?. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 6-8.	6.1	4
8	HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety. <i>American Journal of Nephrology</i> , 2021, 52, 894-898.	3.1	6
9	Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era. <i>Kidney Medicine</i> , 2020, 2, 589-599.e1.	2.0	16
10	Testing Vitamin D Analogues for Vascular Calcification in Patients With CKD. <i>Kidney Medicine</i> , 2020, 2, 385-387.	2.0	0
11	How I treat renal anemia. <i>Blood</i> , 2020, 136, 783-789.	1.4	18
12	Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study. <i>Kidney Medicine</i> , 2020, 2, 307-316.	2.0	9
13	The Value of Intravenous Iron: Beyond the Cave of Speculation. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 896-897.	6.1	8
14	Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study. <i>BMC Nephrology</i> , 2019, 20, 396.	1.8	10
15	Sotatercept Safety and Effects onâ€™Hemoglobin, Bone, and Vascular Calcification. <i>Kidney International Reports</i> , 2019, 4, 1585-1597.	0.8	21
16	PIVOTAL trial: iron loading improves clinical outcomes. <i>Nature Reviews Nephrology</i> , 2019, 15, 260-261.	9.6	4
17	Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease. <i>Kidney Research and Clinical Practice</i> , 2019, 38, 141-144.	2.2	4
18	Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide. <i>American Journal of Nephrology</i> , 2018, 47, 153-161.	3.1	20

#	ARTICLE	IF	CITATIONS
19	The Author Replies. <i>Kidney International Reports</i> , 2018, 3, 218-219.	0.8	1
20	The Author Replies. <i>Kidney International Reports</i> , 2018, 3, 220-222.	0.8	0
21	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 696-705.	0.6	28
22	FP804TWO-YEAR DURABILITY OF IMPROVEMENTS IN EGFR WITH BARDOXOLONE METHYL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: THE LARIAT STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i634-i634.	0.7	0
23	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1113-1117.	2.3	14
24	SP104DECREASES IN WEIGHT WITH BARDOXOLONE METHYL IN OBESE PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i379-i379.	0.7	2
25	Iron Overload in Dialysis Patients: Rust or Bust?. <i>Kidney International Reports</i> , 2017, 2, 995-997.	0.8	8
26	Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease. <i>Kidney International</i> , 2017, 92, 1217-1222.	5.2	20
27	New options for the anemia of chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 157-163.	14.2	35
28	Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data. <i>Clinical Nephrology</i> , 2017, 88, 59-67.	0.7	29
29	A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 646-655.	0.7	70
30	Data confusion. <i>Kidney International</i> , 2015, 88, 1445.	5.2	6
31	Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1238-1247.	6.1	75
32	Update on intravenous iron choices. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 186-191.	2.0	10
33	The KDOQI US Commentary on KDIGO Anemia Guideline and Quality of Life. <i>American Journal of Kidney Diseases</i> , 2014, 63, 540.	1.9	8
34	A Randomized Multicenter Trial of Paricalcitol versus Calcitriol for Secondary Hyperparathyroidism in Stages 3-4 CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1620-1626.	4.5	62
35	Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease. <i>Kidney Research and Clinical Practice</i> , 2013, 32, 11-15.	2.2	15
36	Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2260-2268.	0.7	29

#	ARTICLE	IF	CITATIONS
37	The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. <i>Kidney International</i> , 2012, 82, 235-241.	5.2	81
38	Hepcidin: clinical utility as a diagnostic tool and therapeutic target. <i>Kidney International</i> , 2011, 80, 240-244.	5.2	78
39	The future of intravenous iron in nephrology. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, i6-i9.	2.9	0
40	Anemia management in chronic kidney disease: Intravenous iron steps forward. <i>American Journal of Hematology</i> , 2010, 85, 311-312.	4.1	21
41	It's Time to Compare Anemia Management Strategies in Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 740-742.	4.5	16
42	Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. <i>Kidney International</i> , 2010, 78, 769-773.	5.2	61
43	Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. <i>Lancet, The</i> , 2010, 376, 1543-1551.	13.7	613
44	Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 386-393.	4.5	162
45	Variability of ferritin measurements in chronic kidney disease; implications for iron management. <i>Kidney International</i> , 2009, 75, 104-110.	5.2	51
46	Ethical Issues in Dialysisâ€Aaron Spital, Series Editor: Managing Anemia in Forâ€Profit Dialysis Chains: When Ethics and Business Conflict. <i>Seminars in Dialysis</i> , 2009, 22, 18-21.	1.3	7
47	<i>Mille Verba</i>: Seeking Safe and Efficacious Anemia Management. <i>Seminars in Dialysis</i> , 2009, 22, 590-591.	1.3	5
48	Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2563-2568.	1.8	74
49	Introduction to â€A Road Map for Intravenous Iron and Anemia Management: Preparing for the Futureâ€. <i>American Journal of Kidney Diseases</i> , 2008, 52, S1-S4.	1.9	1
50	A Comprehensive Vision for Intravenous Iron Therapy. <i>American Journal of Kidney Diseases</i> , 2008, 52, S14-S20.	1.9	16
51	Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 372-379.	6.1	150
52	High-Molecular Weight Iron Dextran. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 833-834.	6.1	59
53	Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3â€4 chronic kidney disease. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 364-365.	2.0	14
54	Comment on â€Does ferric gluconate lower epoetin requirements in hemodialysis patients with high ferritin levels?â€. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, E1-E1.	2.0	0

#	ARTICLE	IF	CITATIONS
55	Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate. <i>Nephrology Nursing Journal</i> , 2008, 35, 583-7.	0.2	3
56	Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 975-984.	6.1	362
57	Practice Recommendations Based on Low, Very Low, and Missing Evidence. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 11-12.	4.5	15
58	Influence of Industry on Renal Guideline Development. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 3-7.	4.5	81
59	Treatment of Iron-Deficiency Anemia with IV Ferumoxytol in CKD Patients: Efficacy Compared with Oral Iron across Different Age Groups. <i>Blood</i> , 2007, 110, 2679-2679.	1.4	2
60	Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 263-276.	1.9	198
61	Paricalcitol in the treatment of secondary hyperparathyroidism. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 159-165.	2.4	0
62	Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. <i>Kidney International</i> , 2003, 63, 217-224.	5.2	93
63	Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2002, 40, 1283-1288.	1.9	73
64	Hyperleptinemia in Patients with End-Stage Renal Disease Undergoing Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 1998, 18, 34-40.	2.3	54
65	Increased Plasma Leptin Concentration in End-Stage Renal Disease ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 847-850.	3.6	190